Exhibit
99.1

HCW
Biologics Reports Third Quarter 2026
Business
and Clinical Development Highlights and Financial Results
Miramar,
FL – November 16, 2026 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB),
a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases,
cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and nine months
ended September 30, 2026.
The
Company featured two of its preclinical, non-Fc TRBC molecules at the 41st Annual Meeting of the Society for Immunotherapy
of Cancer (“SITC2026”) which took place from November 4 – 8, 2026 in Phoenix, Arizona. In addition,
the Company showcased the uniqueness of its TRBC platform to create novel multivalent non-Fc fusion molecules for solid tumor and senescence-associated
diseases therapies.
The
submission for the Company’s second-generation, tetravalent immune checkpoint inhibitor, HCW11-040, was recognized by SITC2026
as one of the top 150 abstracts out of over 1,200 abstracts submitted for its scientific rigor, novelty, clarity and potential
impact on cancer immunotherapy. In the Poster presentation of its T Cell Engager Program, the Company shared the newly discovered,
distinctive features of its lead product candidate in this program, HCW11-018b, including capabilities to induce/promote tertiary
lymphoid structure formation inside tumors, convert immunological “cold” tumors into “hot” tumors,
and enhance T-cell activation and tumor infiltration while mitigating immunosuppression, using subcutaneous (“s.c.”) administration.
In
the three months ended September 30, 2026, the Company activated an additional clinical site to participate in the HCW9302 Phase 1 clinical
study in alopecia areata and continued patient enrollment and treatment in the third dose cohort (i.e., eight (8) micrograms/kg body
weight). In patients treated to date, the s.c. administration of HCW9302 has been well-tolerated and has had
no dose-limiting toxicities. With continued patient enrollment, the Phase 1 readout and determination of the Recommended Phase 2 Dose
are expected in the first quarter of 2027. The Company intends to present the full results of the Phase 1 clinical trial in an invited oral
presentation at the 9th Treg-Directed Therapies Summit in March 2027 in Boston, Massachusetts.
Dr. Hing C. Wong, the Company’s Founder
and Chief Executive Officer, stated, “Progress continues steadily for our clinical study evaluating HCW9302 in alopecia
areata, and we are encouraged by results in humans that are consistent with our preclinical studies. We have the support of strong
clinical sites who share our passion for developing breakthrough immunotherapeutics. With the addition of a third clinical site, we
are hopeful that patient enrollment will maintain a good momentum as we come to the end of the Phase 1 clinical study. We
are also excited about the great progress we have made with the molecules we have constructed using our TRBC platform, especially
our lead T-cell engager, HCW11-018b, and our lead second-generation immune-checkpoint inhibitor, HCW11-040, which have the potential
of revolutionizing treatment for solid tumors and senescence-associated diseases.”
Business
and Clinical Development Highlights
In
the nine months ended September 30, 2026, the Company raised $8.6 million of equity financing, which allowed it to continue to support
a Phase 1 clinical study to evaluate HCW9302 in an autoimmune disease and advance preclinical programs, especially the Company’s
T-Cell Engager Program. On November 4, 2026, the Company secured up to $10.0 million in cash through debt financing, and received
$3.0 million, less transaction costs, at closing and access to an additional $7.0 million, subject to certain conditions. With
this financing, the Company believes it has funding in place to reach the milestone of completion of the Phase 1 clinical
trial for HCW9302 and determining the Recommended Phase 2 Dose level, which are expected in the first quarter of 2027.
As
a result of discussions at a recent Type B meeting with the U.S. Food and Drug Administration (“FDA”), the FDA provided the
Company with clear guidance for the next steps to prepare its IND application to support a first-in-human clinical study to evaluate
HCW11-018b in solid tumors, which the Company intends to file in the first half of 2027. In support of potential upcoming clinical trials,
the Company has initiated cGMP manufacturing of HCW11-018b. HCW Biologics has created a high-expression production cell line and
a streamlined GMP manufacturing process, utilizing a relatively simple manufacturing process that is similar to the process used to make
therapeutic monoclonal antibodies.
Third
Quarter 2026 Financial Results
Revenues:
Revenues for the three months ended September 30, 2025 and 2026 were $15,606 and $55,463, respectively. Revenues in the nine months
ended September 30, 2025 and 2026 were $27,222 and $6.7 million, respectively. In the three and nine months ended September 30,
2025, at the request of the licensee, the Company agreed to suspend the license with AlloTera Therapeutics, Inc. (“AlloTera Therapeutics”),
thus the Company recognized revenues related only to minor ancillary services such as storage. In the nine months ended September
30, 2026, the Company elected to terminate the license with AlloTera Therapeutics and recaptured the exclusive rights to the licensed
molecules. In the nine months ended September 30, 2026, the Company completed the closing of the exclusive, worldwide licensing agreement
with Beijing Trimmune Biotech Co., Ltd. (“Trimmune”) for the in vivo rights for HCW11-006 (“Trimmune License”)
and performed additional post-transfer services under the agreement.
Research
and development (R&D) expenses: R&D expenses for the three months ended September 30, 2025 and 2026 were $1.4 million and
$1.2 million, respectively, a decrease of $161,670, or 12%. The decrease was primarily due to decreases in salaries, benefits and related
taxes and preclinical expenses. R&D expenses for the nine months ended September 30, 2025 and 2026 were $4.1 million and $3.7 million,
respectively, a decrease of $405,905, or 10%. The decrease was primarily due to a decline in manufacturing and materials expenses, partially
offset by increases in taxes and salaries, benefits and related expenses.
General
and administrative (G&A) expenses: G&A expenses for the three months ended September 30, 2025 and 2026 were $1.8 million
and $1.4 million, respectively, a decrease of $518,608, or 28%. The decrease was primarily attributable to decreases in stock-based compensation
expense and a decline in fees paid for professional services, such as corporate legal advice, legal advice for prosecution of
patents, auditing and tax services, and other professional services. G&A expenses for the nine months ended September 30, 2025 and
2026, were $6.2 million and $5.1 million, respectively, a decrease of $1.1 million, or 18%. The decrease was primarily attributable
to decreases in stock-based compensation expense, professional services and insurance premiums.
Legal
expenses (recoveries), net: Legal expenses and recoveries, net represent the legal fees that the Company incurred for an Arbitration,
net of insurance recoveries. In the nine months ended September 30, 2025, the Company received a $2.0 million insurance recovery, partially
offset by $409,055 of legal expenses. In the nine months ended September 30, 2026, there were expenses of $14,483. The Company anticipates
it will continue to incur some expenses for the costs of remaining in compliance with the terms of the Settlement and Release Agreement
from the Arbitration, primarily due to requirements for patents which are necessary to protect the Company’s exclusive, worldwide
intellectual property rights held in perpetuity.
Nonoperating
changes impacting net income (loss): In the three months ended September 30, 2025, the was a decrease in fair value of $966,284 related
to the change in the fair value of the Company’s shares in AlloTera Therapeutics and the related contingent liability, and a loss
of $182,146 on the sale of put shares through the Company’s Standby Equity Purchase Agreement. In the three months ended September
30, 2026, there was a $494,683 loss on the return of equipment.
In
the nine months ended September 30, 2025, there was an increase in fair value of $782,404 related to the change in fair value of the
Company’s shares in AlloTera Therapeutics and the related contingent liability, a loss of $182,146 on the sale of put shares through
the Company’s Standby Equity Purchase Agreement. In the nine months ended September 30, 2026, there was a $1.8 million nonoperating
loss, primarily consisting of a $1.8 million decrease in the fair value of a warrant liability, which was reclassified to equity in this
period.
Net
loss: Net loss for the three months ended September 30, 2025 and 2026 was $4.6 million and $3.2 million, respectively. Net loss for
the nine months ended September 30, 2025 and 2026, was $8.7 million and $5.0 million, respectively.
Financial
Guidance
As
of September 30, 2026, the Company believes that substantial doubt exists regarding its ability to continue as a going concern for at
least 12 months from the issuance date of the audited financial statements, without additional funding or financial support. We considered
future elements of our financing plan, but we cannot be assured that we will continue to have success with remaining elements of our
plan.
On
June 26, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was
in compliance with Listing Rule 5550(b)(1) (the “Equity Rule”). On October 2, 2026, the Company received formal notice from
Nasdaq that the Company maintained compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule,” along with all of the applicable
continued listing requirements until September 22, 2026, as required by the Panel decision dated May 29, 2026, as amended.
About
HCW Biologics
HCW
Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion
immunotherapeutics to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated
dysplasia. HCW Biologics is the leader in creation of multi-valent immunotherapeutics with a unique protein-based scaffold, without the
antibody Fc domain. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally
change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and
in doing so, improve patients’ quality of life and possibly extend longevity. A key aspect of the Company’s clinical development
and financing strategy is to focus on its business development programs, including its commercial-ready reagents to be used in the production
of immunotherapeutics for cancer and infectious diseases. To date, the Company has entered into two licensing agreements in which it
has licensed exclusive, worldwide rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/
Forward
Looking Statements
Statements
in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These
statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,”
“believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,”
“forecast” or other similar words. Forward-looking statements are based on the Company’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are difficult to predict, including timing and efficacy in human clinical
trial data for HCW9302, including timing of completion of Phase 1 in the first quarter of 2027, ability of HCW11-018b to treat
solid tumors, ability to obtain U.S. Food and Drug Administration clearance to advance Phase 2 clinical trials for HCW9302, success in
obtaining FDA clearance to initiate clinical trials for HCW11-018b, and effectiveness of commercial-ready reagents for production of
immunotherapeutics; and the Company’s ability to license or sell reagents. Further, certain forward-looking statements are based
on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but
are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report
on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 31, 2026, the Form 10-Q
filed with the SEC on November 16, 2026, and in other filings filed from time to time with the SEC. Forward-looking statements
contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required
under applicable law.
Company
Contact:
Rebecca
Byam
CFO
HCW
Biologics Inc.
rebeccabyam@hcwbiologics.com
HCW
Biologics Inc.
Condensed
Statements of Operations
(Unaudited)
| | |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| | |
2025 | | |
2026 | | |
2025 | | |
2026 | |
| Revenues: | |
| | | |
| | | |
| | | |
| | |
| Revenues | |
$ | 15,606 | | |
$ | 55,463 | | |
$ | 27,222 | | |
$ | 6,734,032 | |
| Cost of revenues | |
| (12,485 | ) | |
| (27,345 | ) | |
| (21,777 | ) | |
| (267,871 | ) |
| Gross Profit | |
| 3,121 | | |
| 28,118 | | |
| 5,445 | | |
| 6,466,161 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating expenses: | |
| | | |
| | | |
| | | |
| | |
| Research and development | |
| 1,404,247 | | |
| 1,242,577 | | |
| 4,109,782 | | |
| 3,703,877 | |
| General and administrative | |
| 1,884,994 | | |
| 1,366,386 | | |
| 6,187,296 | | |
| 5,070,038 | |
| Legal expenses (recoveries), net | |
| 6,006 | | |
| 9,058 | | |
| (1,590,945 | ) | |
| 14,583 | |
| Indirect tax expense | |
| - | | |
| - | | |
| - | | |
| 198,146 | |
| Total operating expenses | |
| 3,295,247 | | |
| 2,618,021 | | |
| 8,706,133 | | |
| 8,986,644 | |
| Operating loss | |
| (3,292,126 | ) | |
| (2,589,903 | ) | |
| (8,700,688 | ) | |
| (2,520,483 | ) |
| Interest expense | |
| (127,070 | ) | |
| (141,797 | ) | |
| (632,923 | ) | |
| (351,612 | ) |
| Change in fair value of contingent liability, net | |
| 1,055,825 | | |
| - | | |
| (692,531 | ) | |
| - | |
| Change in fair value of investment, net | |
| (2,022,109 | ) | |
| - | | |
| 1,474,935 | | |
| - | |
| Change in fair value of warrant liability | |
| - | | |
| - | | |
| - | | |
| (1,775,992 | ) |
| Loss on sale of put shares | |
| (182,146 | ) | |
| - | | |
| (182,146 | ) | |
| - | |
| Loss on return of equipment | |
| - | | |
| (494,683 | ) | |
| - | | |
| (494,683 | ) |
| Gain on extinguishment of liability | |
| - | | |
| - | | |
| - | | |
| 483,383 | |
| Other income, net | |
| 13,290 | | |
| 3,554 | | |
| 54,412 | | |
| 19,992 | |
| Net loss before income taxes | |
| (4,554,336 | ) | |
| (3,222,829 | ) | |
| (8,678,941 | ) | |
| (4,639,395 | ) |
| Income tax expense | |
| - | | |
| - | | |
| - | | |
| (330,186 | ) |
| Net loss | |
$ | (4,554,336 | ) | |
$ | (3,222,829 | ) | |
$ | (8,678,941 | ) | |
$ | (4,969,581 | ) |
| Equity dividend to investor | |
| - | | |
| (2,718,837 | ) | |
| (10,153,799 | ) | |
| (14,361,951 | ) |
| Net loss attributable to Common Stockholders | |
$ | (4,554,336 | ) | |
$ | (5,941,666 | ) | |
$ | (18,832,740 | ) | |
$ | (19,331,532 | ) |
| Net loss per share, basic and diluted | |
$ | (12.09 | ) | |
$ | (2.83 | ) | |
$ | (68.02 | ) | |
$ | (13.35 | ) |
| Weighted average shares outstanding, basic and diluted | |
| 376,678 | | |
| 2,101,872 | | |
| 276,889 | | |
| 1,448,485 | |
HCW
Biologics Inc.
Condensed
Balance Sheets
| | |
December 31, | | |
September 30, | |
| | |
2025 | | |
2026 | |
| | |
| | |
Unaudited | |
| ASSETS | |
| | | |
| | |
| Current assets: | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 1,952,464 | | |
$ | 955,458 | |
| Accounts receivable, net | |
| 32,175 | | |
| - | |
| Prepaid expenses | |
| 222,156 | | |
| 239,998 | |
| Other current assets | |
| 77,564 | | |
| 85,202 | |
| Total current assets | |
| 2,284,359 | | |
| 1,280,658 | |
| Investments | |
| 1,326,329 | | |
| 4,854,028 | |
| Property, plant and equipment, net | |
| 20,880,849 | | |
| 18,963,834 | |
| Other assets | |
| 28,476 | | |
| 28,476 | |
| Total assets | |
$ | 24,520,013 | | |
$ | 25,126,996 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
| Liabilities | |
| | | |
| | |
| Current liabilities: | |
| | | |
| | |
| Accounts payable | |
$ | 13,143,394 | | |
$ | 9,435,785 | |
| Accrued liabilities and other current liabilities | |
| 1,110,104 | | |
| 1,046,440 | |
| Short-term debt, net | |
| 6,809,215 | | |
| 6,831,899 | |
| Deferred revenue | |
| — | | |
| 297,101 | |
| Total current liabilities | |
| 21,062,713 | | |
| 17,611,225 | |
| Contingent liability - related party | |
| 692,531 | | |
| 692,531 | |
| Total liabilities | |
| 21,755,244 | | |
| 18,303,756 | |
| Commitments and contingencies (Note 12) | |
| | | |
| | |
| Stockholders’ equity: | |
| | | |
| | |
| Common stock: | |
| | | |
| | |
| Common, $0.0001 par value; 250,000,000 shares authorized and 546,635 shares issued at December
31, 2025; 250,000,000 shares authorized and 2,236,324 shares issued at September 30, 2026 | |
| 55 | | |
| 223 | |
| Additional paid-in capital | |
| 111,280,560 | | |
| 120,308,443 | |
| Accumulated deficit | |
| (108,515,846 | ) | |
| (113,485,426 | ) |
| Total stockholders’ equity | |
| 2,764,769 | | |
| 6,823,240 | |
| Total liabilities and stockholders’ equity | |
$ | 24,520,013 | | |
$ | 25,126,996 | |